Guy Ralph Perea Sr President of The United States
http://ad.trwv.net/t.pl/54991/261038
http://groups.google.com/group/weatherdata1046am0426
http://columbiabroadcast.spaces.live.com/
http://ptusss.blogspot.com/
ptusss@aol.com
https://www.paypal.com/cgi-bin/webscr?cmd=_donations&business=guyperea@gmail.com&lc=US&item_name=President of The United States&item_number=14112769481¤cy_code=USD&bn=PP-DonationsBF:btn_donateCC_LG.gif:NonHosted
United States Secret Service Director Patty Martinez President Pro Tempro
5 USCS section 5301 (c) "The President's Pay Agent" New in Caution to 'settlement of payment cards" ~ VOUCHERS ~ electronic 26 USCS section 6050W returns 12/31/2010; Travel and Subsistence Expenses; mileage allowance 5 USCS section 5701 without pay or $1.00 a year authorize employment. Confidentality Notice: This E-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the E-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this E-mail is strictly prohibited. If you have received this E-mail transmission in Error, please reply to the sender, so arrangements can be made for proper delivery, and then delete the message from your system. Please consider the environment before printing this email. Notice of Removal of office of Defendant Article IV General Provisions Section 2 (Supreme Law of The Land) The Constitution of The United States. "Any Thing in The Constitution or Laws of any State to the Contrary Notwithstanding" Contrary to Law (of an Act or Omission) Illegal; In Notwithstanding "Dispite;in spite of The government is current Executive Branch violating Notice of Removal, The Notice of Removal on the Obama Administration in personam including Goods (including tea, i.e. Leslie in like); within 30 days after the defendant Barak Obama is served with process in suit (case 641210) 28 USCS section 1446; Murphy Bros., Inc Vs. Michetti Pipe Stringing Inc., 119 S.Ct 1322 (1999). In responce to Housekeeper statment of Court Process of Subject Matter California Inn in Notice of Removal. Create a new office Federal Districts Modesto City Schools Districts and Turlock Irrigation District Division 3; United States Department of Education, Director Ross Carkeet United States Department of Education, Federal Bureau of Investigation Youth Authorty Director Guy Perea, Jr., Federal Bureau of Investigation Youth Authority Director Shopie Perea, and Director United States District Court Western Washington Clean Water United States Navy.
Date: Fri, 4 Feb 2011 09:59:16 -0600
From: fda@service.govdelivery.com
Subject: Drug Information Update- FDA approves Makena to reduce risk of preterm birth in at-risk pregnant women
To: guyperea@live.com
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one spontaneous preterm birth.
The drug is not intended for use in women with a multiple pregnancy, such as a twin pregnancy, or other risk factors for preterm birth.
The FDA approved Makena under the agency's accelerated approval regulations that allow promising drugs to be approved based on a surrogate endpoint benefit (here, reducing the risk of delivery before 37 weeks of pregnancy) that is reasonably likely to predict a clinical benefit.
A health care provider would give Makena once a week by injection into the hip. Treatment should begin at 16 weeks and no later than 21 weeks of pregnancy.
For more information, please visit: Makena
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@govdelivery.com
- Other inquiries? webmail@oc.fda.gov
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA's Division of Drug Information on Twitter: FDA_Drug_Info
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
No comments:
Post a Comment